24-02-2025, 13:00

Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]

Notified -
Globe Newswire24-02-2025, 13:00
1-07-2024, 12:00

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
Globe Newswire1-07-2024, 12:00